Condition
Stage III Renal Cell Cancer AJCC v8 clinical trials and research
As of November 12, 2026, Find a Trial lists 16 Stage III Renal Cell Cancer AJCC v8 clinical trials that are recruiting, at sites in 4 countries (most in United States (16), Australia (1), Canada (1)). By phase: Phase 2 (8), Phase 1 (3), Phase 1/2 (2), Phase 4 (1). The most active sponsors are Mayo Clinic (4), City of Hope Medical Center (3), National Cancer Institute (NCI) (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 16Clinical trials
- 4Countries
Newest Stage III Renal Cell Cancer AJCC v8 clinical trials
All recruiting trials (16)
-
Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC
This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.
-
VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma
This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.
-
Morning versus afternoon immunotherapy for advanced or metastatic solid tumors
This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.
-
Adding a probiotic to standard immunotherapy for advanced kidney cancer
This trial tests whether adding MO-03 probiotic to standard immunotherapy helps people with advanced or metastatic clear cell kidney cancer.
-
Ivonescimab given before surgery for high-risk localized clear cell kidney cancer
This study tests whether giving ivonescimab before nephrectomy helps patients with high-risk localized clear cell renal cell carcinoma.
-
Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma
This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.
-
Adding CBM588 to pembrolizumab after surgery for kidney cancer
This trial tests whether adding CBM588 to pembrolizumab after kidney cancer surgery helps prevent recurrence compared with pembrolizumab alone.
-
Using 18F-TRX to image solid tumors
This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.
-
Inulin gel plus ipilimumab and nivolumab for advanced kidney (renal cell) cancer
This trial tests whether adding an inulin gel to the immunotherapy drugs ipilimumab and nivolumab helps people with locally advanced or metastatic clear cell or sarcomatoid renal cell carcinoma.
-
Predicting how tumors respond to immune therapies using a live diagnostic platform
This study is testing a new way to predict how well immune therapies will work for patients with different types of solid tumors, including early-stage and metastatic cancers.
-
Comparing home and clinic administration of nivolumab for cancer treatment
This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.
-
Genetic testing to choose the best treatment for advanced kidney cancer
This study is testing if using genetic testing to pick the best treatment can help people with advanced kidney cancer respond better to either a combination of immunotherapy drugs or a mix of immunotherapy and targeted therapy.
-
Combining Stereotactic Radiation with Immune Therapy for Advanced Kidney Cancer
This study is testing whether adding a special type of radiation therapy to standard immune treatment can help people with advanced kidney cancer live longer and feel better.
-
Personalized vaccine combined with pembrolizumab for advanced solid tumors
This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.
-
Combining Tumor Treating Fields with Cabozantinib or Pembrolizumab and Nab-Paclitaxel for Advanced Solid Tumors
This study is testing a new treatment that combines tumor treating fields with two different cancer drugs to see if it helps people with advanced solid tumors in the abdomen or chest.
-
Combining three medications for advanced kidney cancer treatment
This study is testing a combination of three medications to see if they can help people with advanced kidney cancer feel better and live longer.
Related topics
Quick answers
How many Stage III Renal Cell Cancer AJCC v8 clinical trials are recruiting right now?
16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (16 trials), Australia (1 trial), Canada (1 trial), Ireland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 8, Phase 1: 3, Phase 1/2: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.